Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material

Journal of Pathology

Volumn 198, Issue 2, 2002, Pages 213-219

  Diestra, Julio E ^a   Scheffer, George L ^b   Català, Isabel ^c   Maliepaard, Marc ^d   Schellens, Jan H M ^d   Scheper, Rik J ^b   Germà Lluch, Jose R ^a   Izquierdo, Miguel A ^a,c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

ABCG2; ATP binding cassette transporters; Breast cancer resistance protein; Drug resistance; Multi drug resistance

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLAVOPIRIDOL; FORMALDEHYDE; IMMUNOGLOBULIN G1; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PARAFFIN; PROTEIN BCRP; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIUM CARCINOMA; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; METHODOLOGY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STAINING; WESTERN BLOTTING;

EID: 0036772386     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1203     Document Type: Article

References (25)

1. Moscow JA, Schneider E, Ivy SP, Cowan KH. Multidrug resistance. Cancer Chemother Biol Response Modifi 1997; 17: 139-177.
2. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for the MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987; 84: 3004-3008.
3. Grant CE, Valdimarsson G, Hipfner DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural products drugs. Cancer Res 1994; 54: 357-361.
4. Kawabe T, Chen ZS, Wada M, et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett 1999; 456: 327-331.
5. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 1999; 96: 6914-6919.
6. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15 665-15 670.
7. Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999; 91: 429-433.
8. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59: 8-13.
9. Allikmets R, Schriml LM, Hutchinson A, et al. A human placenta-specific ATP binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337-5339.
10. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-4563.
11. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59: 5938-5946.
12. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000; 113: 2011-2021.
13. Robey RW, Medina-Pérez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001; 7: 145-152.
14. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000; 96: 365-368.
15. Scheffer GL, Maliepaard M, Pijnenborg ACLM, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 2000; 60: 2589-2593.
16. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal tissues. Cancer Res 2001; 61: 3458-3464.
17. Izquierdo MA, van der Zee AG, Vermorken JB, et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-1237.
18. Rocchi E, Khodjakov A, Volk EL, et al. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 2000; 271: 42-46.
19. Diestra JE. García del Muro X, Zurita AJ. Expression of MDR-proteins LRP, BCRP, MRP1 and P-Gp as predictors of response to neoadjuvant chemotherapy (NACT) and prognosis, in locally-advanced bladder cancer (LABC). Proc Am Soc Clin Oncol 2001; 20: 73A.
20. Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001; 92: 452-458.
21. Zurita AJ, Condom E, García del Muro X. Clinical significance and expression of MDR-proteins LRP and BCRP in testicular germ-cell tumours (TGCT). Proc Am Soc Clin Oncol 2001; 20: 116A.
22. Rabindran SK, Ross DD, Doyle LA, et al. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60: 47-50.
23. De Bruin M, Miyake K, Litman T, et al. Reversal of resistance by GF120918 in cell lines expressing the half transporter, MXR. Cancer Lett 1999; 146: 117-126.
24. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92: 1651-1656.
25. Schellens JHM, Kruijtzer CMF, Rosing H. Complete oral bioavailability of topotecan in combination with the BCRP and P-glycoprotein inhibitor GF120918. Proc Am Soc Clin Oncol 2001; 20: 74A.